A Single-center, Prospective, Randomized Controlled Study of the Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis

What this Trial Is About

Researchers are evaluating the safety and effectiveness of autologous blood transfusion in spinal surgery for patients with lung cancer that has spread to the spine. This study aims to find out if autologous blood transfusion increases new metastases, affects postoperative hemoglobin levels and circulating tumor cells, and reduces the need for allogeneic blood transfusions during and after surgery. This is a single-center, prospective, randomized controlled trial focused on lung cancer spinal metastases. Participants will undergo standard open spinal decompression surgery. When blood transfusion is needed during surgery, patients will receive either autologous blood transfusion combined with a leukocyte filter or allogeneic blood transfusion. Autologous transfusion involves collecting and filtering the patient's own blood lost during surgery, washing and concentrating red blood cells, and then transfusing them back. Blood transfusion decisions depend on bleeding during surgery. The study groups are compared to observe differences in transfusion rates, circulating tumor cells, new metastases, and costs. During the study, researchers will monitor the rate of allogeneic blood transfusion during and after surgery over about one year. They will also measure the number of circulating tumor cells within 30 days after surgery and observe any transfusion-related adverse reactions within 14 days post-surgery. Participants will have assessments of hemoglobin levels and new lesion occurrence. The study lasts on average one year from surgery, with detailed laboratory tests including flow cytometry and tumor cell culture to assess blood samples before and after transfusion.

The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis